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Abstract
Background: Recently, we showed that Sulindac (SU; 320 ppm) reduces precancerous lesions in the colon of Pirc rats,
mutated in the Apc gene. Surprisingly, previous data in Apc-mutated mice showed that SU, with reported efficacy in
Familial Adenomatous Polyposis (FAP), increases colon carcinogenesis. Therefore, we assessed the effect of SU 320 ppm in
a long-term carcinogenesis experiment in Pirc rats. Moreover, since side effects of SU hamper its chronic use and a
combination of drugs could be more effective and less toxic than single agents, we also studied whether two natural
compounds, 3,3’-diindolylmethane (DIM; 250 ppm) and curcumin (CUR; 2000 ppm), with or without lower doses of SU
could affect carcinogenesis
Methods: Pirc rats were fed an AIN76 diet containing SU, DIM and CUR and sacrificed at 8 months of age to measure
intestinal tumours. Apoptosis and proliferation in the normal colon mucosa, as well as gene expression profile were
studied
Results: Colon tumours were significantly reduced by SU 320 ppm (62 % reduction over Controls), by DIM and CUR
without or with SU 80 and 160 ppm (50, 53 and 58 % reduction, respectively) but not by SU 80 ppm alone. Total tumours
(colon and small intestine) were reduced by SU (80 and 320 ppm) and by DIM and CUR. Apoptosis in the normal mucosa
was significantly increased by SU 320 ppm, and slightly increased by DIM and CUR with or without SU. A slight reduction
in Survivin-Birc5 expression was observed with all the treatments compared to Controls. Proliferative activity was not
varied
Conclusions: The results on SU reinforce the validity of Pirc rats to identify chemopreventive products. Moreover, the
efficacy of the DIM and CUR combination to lower colon tumours, suggests an alternative strategy to be exploited in
patients at risk.
Background
The administration of drugs or natural compounds to pre-
vent or slow down the process of colon carcinogenesis
(chemoprevention), has been suggested to lower cancer
risk in patients with familial adenomatous polyposis (FAP)
or individuals with a personal history of sporadic colorectal
cancer (CRC) [1–4]. However, significant side effects asso-
ciated with the use of non-steroidal anti-inflammatory
drugs (NSAID) like Sulindac (SU) or Celecoxib, two of the
most effective chemopreventive drugs, have argued against
their chronic use and evidenced the need for alternative
regimens devoid of toxicity, but still able to lower carcino-
genesis [1]. Indeed, to identify such compounds, one has
to rely on adequate experimental models. Since Apc
gene mutations are a key event in colon carcinogenesis,
rodent models carrying germline mutations in this gene
have been developed and widely used [5, 6]. Pirc rats
(Polyposis in the rat colon) mutated in the Apc gene
(F344/NTac-Apc am1137) were described a few years ago
[7, 8]. At variance with established genetic models like
ApcMin (Min) mice, developing tumours mostly in the small
intestine [5, 6], Pirc rats develop tumours also in the colon,
and are thus potentially a more appropriate model for CRC
and FAP [7, 8]. Recently, we reported that Sulindac (SU,
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320 ppm in the diet) reduces precancerous lesions in the
Pirc rat colon [9]. This result, while suggesting that Pirc rats
might be useful to identify chemopreventive drugs, needs
to be assessed in a long-term carcinogenesis experiment.
Intriguingly, the protective effect of SU in Pirc rats con-
trasts with previous reports in Apc-mutated mice, where
similar dosages of SU decrease small intestinal carcinogen-
esis but increase colon tumours [10, 11].
Curcumin (CUR), an active molecule from Curcuma
longa, shows chemopreventive activity in various experi-
mental settings, and acts, at least in part, to increase apop-
tosis [12–17] and to down-regulate Cyclooxygenase-2
(COX-2), which is overexpressed in colon carcinogenesis
[18]. 3,3’-diindolylmethane (DIM), a derivative of indole-
3-carbinol present in cruciferous plants, has been reported
to lower colon inflammation and tumorigenesis in mice
[19, 20]. Moreover DIM has been shown to synergize with
apoptosis inducers, down-regulating the anti-apoptotic
protein Survin (Birc5), over-expressed in Apc-mutated
cells [20, 21]. Recently, we have shown that the apparently
normal colon mucosa (NM) of Pirc rats over-expresses
Birc5 [9], suggesting that a combination of DIM with an
apoptosis inducer like CUR may reduce colon carcinogen-
esis in these Apc-mutated rats. Accordingly, experimental
studies have shown that a combination of drugs is often
more effective than individual agents [2, 3].
Based on these premises, the aims of this long-term
carcinogenesis experiment in Pirc rats were: 1) to assess
the effect of 320 ppm of SU, the same dosage decreasing
colon precancerous lesions [9]; 2) to study the chemopre-
ventive activity of a combination of DIM (250 ppm) and
CUR (2000 ppm); 3) to study the chemopreventive activity
of a combination of DIM (250 ppm) and CUR (2000 ppm)
with low doses of SU (80 ppm or 160 ppm); 4) to test a
lower dose of SU (80 ppm) alone.
Since SU, CUR and DIM may affect apoptosis and prolif-
eration in the NM and tumours, we studied these parame-
ters. Moreover, we determined the expression of some
genes related to carcinogenesis (Birc5, Casp7, Casp3, Bax,
Bcl2, Cox2) in the NM. Oxidant/pro-oxidant activity, po-
tentially affecting cancer risk, was studied as well [13, 22].
Methods
Animals
Pirc (F344/NTac-Apc am1137) rats were obtained from
Taconic (Taconic Farms, Inc. USA) and bred in CESAL
(University of Florence, Italy) in accordance with the Italian
Guidelines for Animal Care, DL 116/92, application of the
European Communities Council Directive (86/609/EEC).
The Pirc colony was maintained by mating heterozygous
Pirc rats with wild type Fisher F344/NTac rats (Taconic
Farms, Inc. USA); pups were genotyped at one month of
age according to Amos-Landgraf and colleagues [7]. Rats
were maintained in polyethylene cages with wire tops and
bottoms and maintained at a temperature of 22 °C, with a
12:12-h light–dark cycle, under an experimental protocol
approved by the Institutional Animal Care and Use Com-
mittee (IACUC) of the University of Florence and per-
formed according to the Italian Law on Animal Welfare
(DL 116/92). Detailed description of experimental proce-
dures was done in accordance with the ARRIVE guidelines
and could be found in Additional file 1: Table S1
Diet composition and treatments of the animals
Components for the preparation of the AIN76 diet
were purchased from Piccioni (Gessate, Milan, Italy).
SU, DIM and CUR were purchased from Sigma-Aldrich
(Milan, Italy).
For the long-term carcinogenesis experiment, male Pirc
rats, aged 6 weeks, were randomly allocated into: Controls:
fed a standard diet (AIN76 diet) (n = 9); DIM CUR SU 80
group: treated with the same control diet containing SU
(80 ppm in the diet), DIM (250 ppm in the diet according
to Bhatnagar and colleagues [20]) and CUR (2000 ppm as
previously reported [17]) (n = 5); DIM CUR SU 160 group:
treated with the diet containing SU (160 ppm), DIM
(250 ppm) and CUR (2000 ppm) (n = 6); SU 320 group:
treated with the diet containing SU (320 ppm) (n = 4); DIM
CUR group: treated with DIM (250 ppm) and CUR
(2000 ppm) (n = 5); SU 80 group: treated with the diet con-
taining SU (80 ppm) (n = 5).
Assuming for rats a mean body weight of 300 g and 15 g
of daily diet consumption, a diet containing 320 ppm SU
provides 4.8 mg of SU per rat/day, i.e. 16 mg/Kg body
weight. Making the proportion for a man of 70 kg, this
value corresponds to 1120 mg of SU/day, three times
higher than the highest dose of SU recommended for che-
moprevention (400 mg/d) [23]. However, taking into ac-
count the different metabolic rate in humans and rats [24],
and the fact that 320 ppm is the dose with strong chemo-
preventive activity in rats [25], we assumed that 320 ppm,
160 ppm and 80 ppm of SU can be roughly compared to
high, medium and low equivalent doses, respectively, of
SU used for chemoprevention in FAP [23–26].
For carcinogenesis experiments, treatments were contin-
ued up to 8 months of age, and during this time animals
were monitored for body weight and possible rectal bleed-
ing. For the experiments on the effect of SU 320 ppm on
apoptosis, animals (8 controls and 8 SU-treated) were
sacrificed at 2 and 5 months of age (n = 4 in both groups).
Animals were sacrificed by CO2 asphyxia.
Sample collection and tumour analysis
At sacrifice the entire intestine (from pylorus to anus) was
dissected and flushed with cold saline. Starting from the
duodenum, segments of the small intestine (6 cm long)
were longitudinally cut and spread on filter paper with the
mucosa surface upward to assess tumours as described [9].
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Similarly, the entire colon was longitudinally opened and
macroscopic tumours were assessed as described [9]. Tu-
mours were assessed by a researcher (G.C.) who was un-
aware of the experimental codes.
Tumours were enumerated and for each rat a mean
tumour volume was calculated. To do this, we assumed
the tumour as a sphere with a mean diameter that was
evaluated at sacrifice. After this determination, a segment
of apparently morphologically normal mucosa (NM) of the
colon, as well as samples of selected tumours, were dis-
sected and processed for histology in order to study prolif-
erative activity and apoptosis as described below. Sections
stained with haematoxylin and eosin were also used to
determine the type of tumours by histopathological exam-
ination, performed by a pathologist (A.G.) unaware of the
experimental codes. Tumours were evaluated on the basis
of the histotype, grading and pattern of growth, using the
same criteria adopted in human pathology [27, 28]. Accord-
ingly, all the tumours were classified as adenomas with high
or low grade of dysplasia. High grade of dysplasia: is defined
as a lesion showing a moderate-severe grade of dysplasia
corresponding to a carcinoma in-situ or intramucosal car-
cinoma; low grade of dysplasia: is defined as a lesion show-
ing mild grade dysplasia.
Determination of proliferation and apoptosis in the
intestinal mucosa and tumours
Proliferative activity in the apparently morphologically nor-
mal mucosa (NM) was evaluated by determining Proliferat-
ing Cell Nuclear Antigen (PCNA) immunoreactivity in
longitudinal sections of NM, using a mouse monoclonal
antibody (PC-10, Santa Cruz, CA, USA) [29]. Proliferative
activity was evaluated by a single observer on coded sam-
ples, in at least 15 full longitudinal crypt sections of the
NM and expressed as labelling index (LI): the number of
cells positive to PCNA/cells scored × 100 [29].
Apoptosis was evaluated in coded histological longitu-
dinal sections (4 μm thick) of the NM and selected samples
of tumours stained with haematoxylin-eosin, as reported
[29]. An apoptotic index (AI) was determined, that is, the
number of apoptosis/cells scored ×100; we scored at least
1000 cells. In the normal mucosa (NM), apoptosis was
expressed as apoptosis/crypt and at least 15 full longitu-
dinal crypt sections were scored.
Semi-quantitative RT-PCR and oxidant/antioxidant status
in the plasma
Gene expression was evaluated in the apparently normal
colon mucosa (NM), taken at the sacrifice as described [9].
The primers used for the amplification of the different
genes have been previously described [9]. For each target
gene, the relative amount of mRNA in the samples was
calculated as the ratio of each gene to β-actin mRNA [9].
The determination of Reactive Oxygen Species (ROS),
ferric reducing ability of plasma (FRAP) and carbonyl
residues (CO) in the plasma, was carried out as previ-
ously described [9].
Statistical evaluation of the data
Data obtained from individual rats in the different experi-
mental groups were summarised for quantitative continu-
ous responses by calculating group means and standard
deviations. Comparisons among the different groups were
analysed with one-way ANOVA, post-hoc comparisons
were analysed with Bonferroni’s test for multiple compari-
son performed with Graph-pad (p-level fixed at 0.05, two-
sided). The effect of SU 320 ppm on apoptosis was also
evaluated in two separate short-term treatment experi-
ments (1 and 4 months of treatment). In this case, we used
two-way ANOVA to evaluate the effect of Sulindac and, at
the same time, that of the different experiment.
Results
The mean weight of the rats at the beginning of the long-
term carcinogenesis experiment (6 weeks of age) was 180 ±
8 g (means ± SE, n = 34). At sacrifice, when the animals
were 8 months old, the mean weight was similar among
dietary groups, with no apparent signs of toxicity from the
treatments (445 ± 15 g, 461 ± 14 g, 420 ± 18 g, 456 ± 10 g,
429 ± 13 g and 406 ± 2 g; means ± SE, in Controls, DIM
CUR SU 80, DIM CUR SU 160, SU 320, DIM CUR and SU
80 groups, respectively).
The determination of tumours showed that in all the
experimental groups (Fig. 1, panel a), with the exception
of the SU 80 ppm group, the number of tumours in the
colon was significantly lower than in Controls. The vol-
umes of these tumours were similar among groups (data
not shown).
Regarding the small intestine, none of the treatments
significantly varied the number of tumours in the small
intestine (Fig. 1, panel b). However, in the experimental
groups the volumes of the small intestinal tumours were
slightly smaller than in the Control group (mean volumes
(mm3) were: 52.4 ± 10.0 [9], 25.4 ± 10.1 [5], 20.0 ± 4.5 [6],
19.5 ± 5.1 [4], 22.4 ± 4.1 [5] and 28.2 ± 6.0 [5] in Controls,
DIM CUR SU 80, DIM CUR SU 160, SU 320, DIM CUR
and SU 80 groups, respectively; (number of rats in each
group)), and the DIM CUR SU 160 was significantly lower
(P < 0.05) than the Control group.
Considering the total number of tumours (i.e. both co-
lonic and small intestinal tumours), a significant lower
number of tumours was observed in the groups treated
with 320 ppm and 80 ppm of SU as well in the DIM CUR
group (Fig. 1, panel c).
In a subset of colon tumours (n = 17, 10, 13, 10, 7, 8, in
Controls, DIM CUR SU 80, DIM CUR SU 160, SU 320,
DIM CUR and SU 80 groups, respectively) we determined
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the histology and the level of apoptosis (Fig. 2). All the
tumours were classified as adenomas; interestingly, the per-
cent of highly dysplastic adenomas tends to be lower in the
CUR DIM and SU 320 compared to Controls (Fig. 2, panel
a). Apoptosis in the same subset of tumours was similar
among the groups (Fig. 2, panel b).
We also measured apoptosis in the NM and found that
the highest dose of SU (320 ppm) caused a significant
increase in apoptosis compared with Controls (Fig. 3,
panel a). The groups treated with DIM CUR with or with-
out the combination of SU, also showed a number of
apoptotic cells slightly higher than Controls, but the effect
was not statistically significant (Fig. 3, panel a).
The effect of the high dose of SU (320 ppm) on apoptosis
was then confirmed in Pirc rats treated with the same dose
for a shorter period (1 or 4 months), a time sufficient to
decrease the number of precancerous lesions in the colon
[9]. Indeed, with these short-term administrations as well,
rats treated with SU showed a significantly higher apoptosis
than Controls (Fig. 3, insert in panel a). Proliferative activity
in the NM was similar among groups (Fig. 3 panel b).
In order to understand the molecular mechanisms of
action underlying the protective effects observed in the
colon, we studied the expression of some genes affecting
apoptosis and tumour development in the apparently nor-
mal colon mucosa (NM). Birc5 (Survivin, Fig. 4, panel a)
expression was slightly, although not significantly, lower
in treated groups compared with Controls. Similarly, the
expression of other apoptosis-related genes (Bax, Bcl2,
Casp 3 and Casp7) was not varied (Fig. 4, panels b, c, d
and e). Cox2 gene expression was also similar among
groups (Fig. 4, panel f).
Plasma FRAP did not vary significantly among groups
(108 ± 8 μM [5], 140 ± 27 μM [5], 167 ± 25 μM [6], 121 ±
10 μM [3], 152 ± 43 μM [5] and 192 ± 61 μM [5] in Con-
trols, DIM CUR SU 80, DIM CUR SU 160, SU 320, DIM
CUR and SU 80 groups, respectively, means ± SE (n)). Simi-
larly, ROS and CO did not vary (data not shown).
Discussion
SU was the first NSAID to show chemopreventive activity
in FAP patients [4]. Several studies have thereafter con-
firmed its ability to reduce the number of adenomas in the
colon and rectum [1, 4]. Despite the fact that FAP patients
on SU may still develop adenocarcinomas, chronic treat-
ment with this drug has been suggested as an option to
postpone surgery [1, 4].
SU treatment has also been demonstrated to decrease
carcinogenesis in carcinogen-induced models of colon can-
cer [25]. Surprisingly, studies in Min mice, showed that SU
increased carcinogenesis in the colon, raising perplexities
on the validity of that genetic model to identify chemopre-
ventive drugs for colon cancer [10, 11, 30]. Recently, we
reported that 320 ppm of SU in the diet decreases precan-
cerous lesions in the colon of Pirc rats [9]. The results of
the present study, obtained in a long-term carcinogenesis
study, showed that SU 320 ppm decreased colon and total
tumors. Therefore, while confirming our previous results
on preneoplastic lesions, these results indicate that indeed
the Pirc rat may be a valid model to identify chemopreven-
tive agents.
We also found that 80 ppm of SU tends to lower carcino-
genesis in both the colon and small intestine, giving a statis-
tically significant reduction only with respect to the total
number of tumours (Fig. 1, panel c). A similar slight effect
of this SU dose has been reported in carcinogen-induced
rats [31], suggesting, together with the results of clinical
studies in FAP, that higher doses of SU are indeed necessary
to afford a full chemopreventive effect in the colon [1, 32].
Although SU has not been associated with serious cardio-
vascular effects such as those caused by COX-2 selective
inhibitors, chronic use of this drug at relatively high doses
Fig. 1 Mean number of tumours/rat in the colon (panel a), in the small intestine (panel b) and in the entire intestine (colon and small intestine
together) (panel c), in the various experimental groups. Bars represent mean values + SE. The number of rats per group were: 9 in Controls, 5 in
DIM CUR SU 80, 6 in DIM CUR SU 160, 4 in SU 320, 5 in DIM CUR and 5 in SU 80 groups. **, *: significantly different (P < 0.01, P < 0.05, respectively)
compared with Controls
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can expose the patients to gastrointestinal toxicity [1, 23].
Accordingly, in the present study we were also interested
in studying the chemopreventive activity of a combination
of DIM (250 ppm) and CUR (2000 ppm) with or without
lower doses of SU (80 ppm or 160 ppm).
Regarding CUR and DIM given together without SU,
we observed that this combination was able to lower car-
cinogenesis in the colon, and, although not significantly,
also in the small intestine. On the contrary, when DIM and
CUR were administered together with 160 or 80 ppm of
SU, we observed that while in the colon these combinations
showed a protective effect, this effect was not observed in
the small intestine.
Therefore, taken together, our results show that
addition of SU to CUR and DIM did not afford further
protection compared to the combination of CUR and
DIM on its own.
It is also interesting to note that regarding colon tumours,
and the total number of tumours, the chemopreventive
activity of the combination of DIM and CUR is comparable
to the effect afforded by 320 ppm of SU. Therefore, long-
term treatment with a combination of CUR and DIM could
be envisaged to prevent tumours in FAP patients. In fact, a
combination of CUR and Quercetin administered for six
months has been reported to be tolerated and effective in
reducing adenomas in FAP, although side-effects possibly
emerging after longer periods are not known [33]. Since
chemoprevention in FAP requires long treatments, a pos-
sible strategy to reduce potential toxicity without lowering
the chemopreventive effectiveness could be to alternate SU
with a combination of CUR and DIM.
Regarding the mechanism of action, we found that at
least SU 320 ppm, significantly increased apoptosis in the
NM, in line with previous data in FAP patients [34]. We
Fig. 2 Panel a: percent of tumours in the various experimental groups showing high or low dysplasia. Panel b: Apoptotic index (AI) in the
tumours of the various groups (in both panels: n = 17, 10, 13, 10, 7, 8, in Controls, DIM CUR SU 80, DIM CUR SU 160, SU 320, DIM CUR and SU 80
groups, respectively)
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also observed that even a shorter period of treatment with
SU 320 ppm (one or four months) was able to increase
apoptosis in the NM, further reinforcing the data observed
in the long-term carcinogenesis experiment.
Regarding CUR and DIM, previous studies have shown
that CUR increases apoptosis in the small intestinal mu-
cosa of Min mice [14, 16], while DIM may synergize
with apoptosis inducers like butyrate through down-
regulation of the anti-apoptotic molecule survivin [20].
We observed that all the experimental diets caused a slight
down-regulation of the anti-apoptotic gene Survivin (Birc5),
which is up-regulated in Pirc rats compared to wt rats [9],
while we did not find differences in the expression of other
apoptosis related genes. Only a slight increase in apoptosis
was observed in the groups treated with diets containing
DIM and CUR. Given the efficacy of these experimental
diets to lower colon carcinogenesis, although we can specu-
late that their chemopreventive effect may be due to an
increase in apoptosis in NM, additional mechanisms of
action, to be further investigated, are probably involved.
Since higher proliferative activity in the colon mucosa
has been associated with an increased risk of developing
cancer [35], we measured this parameter in the NM. Prolif-
erative activity was not affected by the dietary treatments.
Regarding SU, this result is in line with previous studies
in FAP patients in which SU did not cause a variation
Fig. 3 Panel a: apoptosis/crypt in the apparently normal mucosa (NM) of the various experimental groups. Bars represent mean + SE. n = 8, 5, 6, 4, 5, 5
in Controls, DIM CUR SU 80, DIM CUR SU 160, SU 320, DIM CUR and SU 80 groups, respectively. **: significantly different (P < 0.01) when compared
with Controls. Insert of panel a: apoptosis/crypt in the NM of rats treated with a Control diet or with the same diet supplemented with SU 320 ppm
for 1 or 4 months. Bars represent mean numbers + SE. n = 4 in each group. **: significantly different (P < 0.05) compared with Controls (with two-way
analysis of variance for the effect of Sulindac). Panel b: proliferative activity, expressed as LI (labelling index) in the NM of the different groups. Bars are
means + SE. n = 7, 5, 5, 4, 3, 4 in Controls, DIM CUR SU 80, DIM CUR SU 160, SU 320, DIM CUR and SU 80 groups, respectively
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in proliferative activity in the NM [34, 36]. As for CUR
and DIM, both have been shown to arrest cell prolifer-
ation of cancer cells in vitro [15, 37], while in vivo
studies showed an increase in cell proliferation in Min
mice treated with CUR 1000 ppm [14]. To our know-
ledge, no previous studies evaluated the effect of DIM
on the proliferative activity of the colon.
Due to the large number of colon tumours present in
the Pirc rats, it was not possible to study the histology
and the level of apoptosis in each tumour. Therefore,
we selected a subset of tumours from each dietary
group, which were shown to be adenomas of various
grades of dysplasia. Interestingly, although the volume
of this subset of tumours was similar, the percent of
highly dysplastic adenomas tended to be lower in the
CUR DIM and SU 320 compared to Controls. On the
contrary, despite previous reports indicating a pro-
apoptotic effects of SU, CUR and DIM also in tumour
cells [20, 38, 39], we did not observe variation in
apoptosis.
Fig. 4 Relative expression of Birc5, Bax, Bcl2,Casp3, Casp7, Cox2 (panels a, b, c, d, e and f, respectively) in the colon mucosa of the
variousexperimental groups. Bars represent means ± SE, n =8, 5, 6, 3, 5 and 5 in Controls, DIM CUR SU 80, DIM CUR SU 160, SU 320, DIM
CUR and SU 80 groups, respectively
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Conclusions
In conclusion, we showed that colon tumours in Pirc rats
were significantly reduced by SU 320 ppm and by DIM and
CUR with or without SU 80 and 160 ppm. The efficacy of
the DIM and CUR combination to lower colon tumours in
this relevant model of colon cancer, suggests an alternative
strategy to be exploited in patients at risk.
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